basiliximab + mycophenolate mofetil + tacrolimus

This is a combination immunosuppressive regimen consisting of basiliximab, mycophenolate mofetil, and tacrolimus. It is primarily used to prevent acute rejection in solid organ transplantation, especially kidney and liver transplants. Basiliximab is a chimeric monoclonal antibody that targets the interleukin-2 receptor alpha chain (CD25) on activated T lymphocytes, thereby inhibiting IL-2-mediated activation and proliferation of T cells involved in allograft rejection. Mycophenolate mofetil is an antimetabolite immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH), suppressing lymphocyte proliferation by blocking de novo guanosine nucleotide synthesis. Tacrolimus is a calcineurin inhibitor that blocks T-cell activation by inhibiting the phosphatase activity of calcineurin, thus preventing transcription of interleukin-2 and other cytokines critical for T-cell function. This triple-drug regimen reduces the risk of acute rejection while allowing for lower doses of individual agents to minimize toxicity[1][4][5][6][8].